← Leaderboards
Kwok Kin Wong
New York University School Of Medicine
$31,472,345
Attributed
$51,986,284
Total exposure
24
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$51,986,284 · 24
By mechanism
R01$38,815,479 · 15
U01$7,435,995 · 2
P01$5,087,974 · 5
K08$630,450 · 1
P30$16,386 · 1
Top collaborators
- Donald W. Kufe21 shared
- John V. Heymach9 shared
- Jeffrey A Engelman7 shared
- Nabeel Bardeesy5 shared
- Nathanael Schiander Gray5 shared
- Carla F. Kim5 shared
- Benjamin G. Neel5 shared
- Norman Edward Sharpless5 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Benjamin G. Neel$33,134,772
- Dan R Littman$30,444,906
- Kari E Hacker$1,374,992
- Thales Papagiannakopoulos$8,767,709
- Kelsey R Monson$170,583
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationMalignant Neoplasm Of LungTumorMouse ModelIn VivoGenetically Engineered MouseMalignant NeoplasmsResponsePathway InteractionsOncogenicMutantNon-Small-Cell Lung CarcinomaCancer PatientResistanceInhibitor/AntagonistBaseCellsEpidermal Growth Factor ReceptorImmuneTargeted TreatmentCancer CellGenesSignal TransductionKras2 Gene
Grant awards (112)
Targeting cell state transitions driving resistance to KRAS inhibitors in lung cancer$718,258
R01 · FY2025 · CA · contact PI
Targeting molecular mechanisms of the adeno-to-squamous transition in non-small cell lung cancer treatment adaptation$703,410
R01 · FY2025 · CA
Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer$702,059
R01 · FY2025 · CA
Combining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancer$673,898
R01 · FY2025 · CA · contact PI
Impact of recurrent genetic alterations on SCLC subtypes and therapeutic response$351,713
P01 · FY2025 · CA · contact PI
Targeting cell state transitions driving resistance to KRAS inhibitors in lung cancer$735,635
R01 · FY2024 · CA · contact PI
Combining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancer$734,981
R01 · FY2024 · CA · contact PI
Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer$666,956
R01 · FY2024 · CA
Therapeutic strategies against EGFR exon 20 mutant lung cancer$529,607
R01 · FY2024 · CA
Impact of recurrent genetic alterations on SCLC subtypes and therapeutic response$351,713
P01 · FY2024 · CA · contact PI
Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer$688,018
R01 · FY2023 · CA
Therapeutic strategies against EGFR exon 20 mutant lung cancer$546,332
R01 · FY2023 · CA
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies$829,650
U01 · FY2022 · CA
Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer$688,018
R01 · FY2022 · CA
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.$663,862
R01 · FY2022 · CA
Mechanisms of tumorigenesis in Brg1 mutant lung cancer$632,407
R01 · FY2022 · CA
Therapeutic strategies against EGFR exon 20 mutant lung cancer$546,332
R01 · FY2022 · CA
Dectin-1 signaling drives pancreatic oncogenesis by inducing macrophage-mediated adaptive immune suppression$379,977
R01 · FY2022 · CA · contact PI
Project 3 - Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer$163,031
P01 · FY2022 · CA · contact PI
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies$829,650
U01 · FY2021 · CA
Response and resistance to SHP2 inhibitors alone and in combination in Non-Small Cell Lung Cancer$703,176
R01 · FY2021 · CA
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.$677,442
R01 · FY2021 · CA
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer$656,426
U01 · FY2021 · CA · contact PI
Mechanisms of tumorigenesis in Brg1 mutant lung cancer$650,128
R01 · FY2021 · CA
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$618,912
R01 · FY2021 · CA
Therapeutic strategies against EGFR exon 20 mutant lung cancer$557,481
R01 · FY2021 · CA
Dectin-1 signaling drives pancreatic oncogenesis by inducing macrophage-mediated adaptive immune suppression$387,731
R01 · FY2021 · CA · contact PI
Core C: Animal Modeling and Preclinical Therapeutics$263,824
P01 · FY2021 · CA · contact PI
Tumor Immunology (TIM) Research Program$16,386
P30 · FY2021 · CA · contact PI
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies$829,650
U01 · FY2020 · CA
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.$677,471
R01 · FY2020 · CA
Mechanisms of tumorigenesis in Brg1 mutant lung cancer$654,799
R01 · FY2020 · CA
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer$629,612
U01 · FY2020 · CA · contact PI
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$624,332
R01 · FY2020 · CA
Therapeutic approaches for LKB1-deficient non-small cell lung cancer$605,252
R01 · FY2020 · CA
Therapeutic strategies against EGFR exon 20 mutant lung cancer$572,983
R01 · FY2020 · CA
Dectin-1 signaling drives pancreatic oncogenesis by inducing macrophage-mediated adaptive immune suppression$548,509
R01 · FY2020 · CA · contact PI
Core C: Animal Modeling and Preclinical Therapeutics$263,824
P01 · FY2020 · CA · contact PI
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies$829,650
U01 · FY2019 · CA
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.$657,955
R01 · FY2019 · CA
Mechanisms of tumorigenesis in Brg1 mutant lung cancer$639,553
R01 · FY2019 · CA
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer$636,731
U01 · FY2019 · CA · contact PI
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$611,442
R01 · FY2019 · CA
Therapeutic approaches for LKB1-deficient non-small cell lung cancer$587,093
R01 · FY2019 · CA
Core C: Animal Modeling and Preclinical Therapeutics$264,777
P01 · FY2019 · CA · contact PI
MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies$829,650
U01 · FY2018 · CA
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.$726,766
R01 · FY2018 · CA
Mechanisms of tumorigenesis in Brg1 mutant lung cancer$683,713
R01 · FY2018 · CA
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer$661,067
U01 · FY2018 · CA · contact PI
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$636,708
R01 · FY2018 · CA
Therapeutic approaches for LKB1-deficient non-small cell lung cancer$605,252
R01 · FY2018 · CA
Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer$474,931
P01 · FY2018 · CA · contact PI
Core C: Animal Modeling and Preclinical Therapeutics$263,824
P01 · FY2018 · CA · contact PI
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$180,136
R01 · FY2018 · CA
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer$703,909
U01 · FY2017 · CA · contact PI
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$642,150
R01 · FY2017 · CA
Therapeutic approaches for LKB1-deficient non-small cell lung cancer$605,252
R01 · FY2017 · CA
Credentialing Mouse Models for Immune System Therapy Research$581,304
R01 · FY2017 · CA
Therapeutic strategies for specific subsets of KRAS mutant lung cancers$559,228
R01 · FY2017 · CA · contact PI
Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer$474,931
P01 · FY2017 · CA · contact PI
Core C: Animal Modeling and Preclinical Therapeutics$263,825
P01 · FY2017 · CA · contact PI
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer$126,024
R01 · FY2017 · CA
Credentialing Mouse Models for Immune System Therapy Research$581,304
R01 · FY2016 · CA
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$534,201
R01 · FY2016 · CA
Therapeutic strategies for specific subsets of KRAS mutant lung cancers$512,243
R01 · FY2016 · CA · contact PI
Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer$474,931
P01 · FY2016 · CA · contact PI
In vivo murine models of metastasis for therapeutic testing$400,209
R01 · FY2016 · CA
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$116,603
R01 · FY2016 · CA
Animal Models/Experimental Therapeutics Core$80,784
P01 · FY2016 · CA · contact PI
Credentialing Mouse Models for Immune System Therapy Research$588,966
R01 · FY2015 · CA
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$534,201
R01 · FY2015 · CA
Therapeutic strategies for specific subsets of KRAS mutant lung cancers$512,243
R01 · FY2015 · CA · contact PI
Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer$474,931
P01 · FY2015 · CA · contact PI
In vivo murine models of metastasis for therapeutic testing$400,209
R01 · FY2015 · CA
In vivo analysis of EGFR mutant driven lung cancers responses to radiation therap$282,228
R01 · FY2015 · CA · contact PI
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$89,819
R01 · FY2015 · CA
Animal Models/Experimental Therapeutics Core$80,784
P01 · FY2015 · CA · contact PI
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$518,175
R01 · FY2014 · CA
Therapeutic strategies for specific subsets of KRAS mutant lung cancers$496,876
R01 · FY2014 · CA · contact PI
Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer$483,794
P01 · FY2014 · CA · contact PI
In vivo murine models of metastasis for therapeutic testing$388,202
R01 · FY2014 · CA
In vivo analysis of EGFR mutant driven lung cancers responses to radiation therap$273,761
R01 · FY2014 · CA · contact PI
Animal Models/Experimental Therapeutics Core$78,360
P01 · FY2014 · CA · contact PI
Therapeutic strategies for specific subsets of KRAS mutant lung cancers$530,993
R01 · FY2013 · CA · contact PI
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$502,149
R01 · FY2013 · CA
In vivo murine models of metastasis for therapeutic testing$376,196
R01 · FY2013 · CA
In vivo analysis of EGFR mutant driven lung cancers responses to radiation therap$265,295
R01 · FY2013 · CA · contact PI
Animal Models/Experimental Therapeutics Core$190,898
P01 · FY2013 · CA · contact PI
Functional role of the MUC1-C oncoprotein in non-small cell lung cancer$534,201
R01 · FY2012 · CA
Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer$496,412
R01 · FY2012 · CA · contact PI
In vivo murine models of metastasis for therapeutic testing$412,209
R01 · FY2012 · CA
In vivo analysis of EGFR mutant driven lung cancers responses to radiation therap$282,228
R01 · FY2012 · CA · contact PI
Animal Models/Experimental Therapeutics Core$87,099
P01 · FY2012 · CA · contact PI
Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer$496,752
R01 · FY2011 · CA · contact PI
In vivo analysis of EGFR mutant driven lung cancers responses to radiation therap$282,228
R01 · FY2011 · CA · contact PI
Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer$476,188
R01 · FY2010 · CA · contact PI
EGFRvIII Mutation in Tumorigenesis and Sensitivity to Tyrosine Kinase Inhibitors$277,591
R01 · FY2010 · CA · contact PI
Dysfunctional Telomeres, Checkpoints and Aging$266,304
R01 · FY2010 · AG · contact PI
Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer$434,462
R01 · FY2009 · CA · contact PI
EGFRvIII Mutation in Tumorigenesis and Sensitivity to Tyrosine Kinase Inhibitors$277,591
R01 · FY2009 · CA · contact PI
Dysfunctional Telomeres, Checkpoints and Aging$269,903
R01 · FY2009 · AG · contact PI
EGFRvIII Mutation in Tumorigenesis and Sensitivity to Tyrosine Kinase Inhibitors$277,591
R01 · FY2008 · CA · contact PI
Dysfunctional Telomeres, Checkpoints and Aging$270,786
R01 · FY2008 · AG · contact PI
EGFRvIII Mutation in Tumorigenesis and Sensitivity to Tyrosine Kinase Inhibitors$277,591
R01 · FY2007 · CA · contact PI
Dysfunctional Telomeres, Checkpoints and Aging$277,187
R01 · FY2007 · AG · contact PI
Modeling Lung Cancer in Telomerase Null Mice$126,090
K08 · FY2007 · AG · contact PI
Dysfunctional Telomeres, Checkpoints and Aging$286,340
R01 · FY2006 · AG · contact PI
EGFRvIII Mutation in Tumorigenesis and Sensitivity to Tyrosine Kinase Inhibitors$285,500
R01 · FY2006 · CA · contact PI
Modeling Lung Cancer in Telomerase Null Mice$126,090
K08 · FY2006 · AG · contact PI
Modeling Lung Cancer in Telomerase Null Mice$126,090
K08 · FY2005 · AG
Modeling Lung Cancer in Telomerase Null Mice$126,090
K08 · FY2004 · AG
Modeling Lung Cancer in Telomerase Null Mice$126,090
K08 · FY2003 · AG